AMU, AP-HM, VRCM
Education is also one of the strategic components of the Marseille Immunopole project
Advances in science and technology have gradually abolished the frontier between fundamental research and the clinic. Like most founders of Marseille Immunopole, my every day life consists in constant back and forth between the laboratory and the patient’s bedside and I work at the interface of several disciplines, technologies and application fields: immunology and haematology, cell therapy and monoclonal antibodies, diagnosis and therapy. We work also, of course, with industry that now constitutes a key player to accelerate the transfer of these innovations to the clinic.
My common theme remains the vessel. In VRCM, vessels can be destroyed to starve tumours or conversely rebuilt to restore blood flow in ischemic stroke, lower extremity arterial diseases, etc. With the haematology service of the Conception Hospital, we have also developed innovative vascular biomarkers by measuring the concentration and origin of blood microparticles released by damaged cells, so clinicians can now improve the diagnosis and monitoring of patients with cardiovascular diseases, cancers, autoimmune and inflammatory diseases.
With the cell therapy unit of Florence Sabatier, our team is also involved in regenerative medicine. We base this on an unexplored source of stem cells that lies at the core of adipose tissue: the stromal vascular fraction. The early clinical data we have obtained from scleroderma, a rare and debilitating autoimmune disease, seem already to confirm the potential of this new approach. Education is also one of the strategic components of the Marseille Immunopole project. As Dean of the Faculty of Pharmacy, my goal is also to prepare the next generation: to fuel research and industry with new talent, but also to familiarise future pharmacists with new drugs arising from these innovations.#clinique #recherche
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
AMU, Gustave Roussy, The Pioneer Project